ATAZANAVIR CIPLA atazanavir 300 mg capsule bottle pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

atazanavir sulfate, Quantity: 341.71 mg (Equivalent: atazanavir, Qty 300 mg)

Disponible desde:

Cipla Australia Pty Ltd

Designación común internacional (DCI):

Atazanavir sulfate

formulario farmacéutico:

Capsule, hard

Composición:

Excipient Ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; Gelatin; sodium lauryl sulfate

Vía de administración:

Oral

Unidades en paquete:

30 capsules, 60 capsules

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (See Clinical Trials).

Resumen del producto:

Visual Identification: White to pale yellow granules filled in size 00 hard gelatin capsule with maroon cap & white body spin printed with 'Cipla 300' on cap with white ink.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 15 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Estado de Autorización:

Licence status A

Fecha de autorización:

2017-08-30